Abiopharma

🔍 Scanlon Jennifer F. (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 9,532 shares of Class A Common Stock at $91.4294 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: false | shares_owned_after: 191,242.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,968 shares of Class A Common Stock at $92.0117 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: false | shares_owned_after: 188,274.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 89,285.00

Footnotes:

• F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
• F2: This transaction was executed in multiple trades at prices ranging from $90.84 to $91.83, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: This transaction was executed in multiple trades at prices ranging from $91.84 to $92.41, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.